GlassScriptPhysician profile
Sreedhar Chava
NPI 1255515383
$2,271.56
in general payments reported to CMS, 2019-2025
30 companies · $462 in 2025
The $462 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $202 · 2020: $19.69 · 2021: $142 · 2022: $281 · 2023: $471 · 2024: $695 · 2025: $462.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,627.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,627.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $633.69 | 2019-2025 | Gardasil 9, Vaxneuvance, Vaxelis |
| Sanofi Pasteur INC. | $228.50 | 2021-2025 | |
| Amgen INC. | $136.66 | 2024-2025 | Repatha, Otezla, Otezla |
| Glaxosmithkline, LLC. | $124.72 | 2019-2025 | Bexsero, Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $114.90 | 2021-2025 | |
| Pfizer INC. | $105.23 | 2019-2024 | |
| Cranial Technologies, INC | $101.79 | 2019-2025 | Doc Band |
| Shield Therapeutics INC | $94.75 | 2024 | |
| Xeris Pharmaceuticals, INC. | $85.44 | 2023-2024 | Gvoke Hypopen |
| Astrazeneca Pharmaceuticals LP | $81.85 | 2022-2025 | Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $68.58 | 2022-2024 | Xifaxan |
| Lilly USA, LLC | $57.20 | 2022-2025 | Zepbound, Mounjaro |
| Agile Therapeutics, INC. | $57.08 | 2021-2023 | Twirla |
| Ultragenyx Pharmaceutical INC. | $43.91 | 2023-2024 | Crysvita |
| Janssen Pharmaceuticals, INC | $41.32 | 2022-2023 | Xarelto |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.16 | 2021 | |
| Abbvie INC. | $34.94 | 2021-2022 | |
| Exact Sciences Corporation | $32.98 | 2025 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $25.00 | 2022 | |
| Dermira, INC. | $21.60 | 2019 | |
| Almatica Pharma LLC | $21.54 | 2022 | |
| Roche Diagnostics Corporation | $19.98 | 2019 | |
| Boston Scientific Corporation | $19.69 | 2020 | |
| Allergan, INC. | $19.62 | 2019 | |
| Organon LLC | $19.03 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $17.74 | 2023 | Eliquis |
| Scilex Pharmaceuticals INC. | $16.01 | 2024 | |
| Avion Pharmaceuticals | $11.65 | 2021 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sreedhar Chava listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.